CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Almac Group Launches Bespoke Elemental Impurities Laboratory

The pharmaceutical industry is currently facing stringent new demands on elemental impurities from regulators stipulating the control and documentation of elemental ...
Continue Reading →
News

Saneca Pharma strengthens team with new sales director

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has strengthened its team with the appointment of a new CDMO sales director a...
Continue Reading →
News

PCI Announces Appointment to its Manufacturing Business Development Team

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jennifer Goldberg to its Manufacturing Business Development...
Continue Reading →
News

Elpis BioMed closes funding round to commercialise novel technology platform for generating human cell types

Elpis BioMed Ltd (Elpis), a University of Cambridge spin-out, applying its disruptive and proprietary “direct cell reprogramming” platform to produce pure, mature an...
Continue Reading →
News

Immuno-oncology CRO secures Macrophage Pharma agreement

Aquila BioMedical Ltd., an innovative preclinical contract research organisation (CRO) now part of Concept Life Sciences group, has secured an extended agreement wit...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026